micro-community-banner
Profile Image
  • Saved
Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial

Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial

Source : https://bmjopen.bmj.com/content/13/7/e072541

Introduction Percutaneous coronary intervention (PCI)-related myocardial infarction (type 4a MI) and major periprocedural myocardial injury have been demonstrated leading to poor prognosis of patients with coronary heart disease (CHD) undergoing...

Strengths: This study will provide new evidence of the efficacy of alirocumab on preventing percutaneous coronary intervention (PCI)-related myocardial infarction or major periprocedural myocardial injury in patients with coronary heart disease undergoing elective PCI.

Profile Image
  • Saved
Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary - The Egyptian Heart Journal

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary - The Egyptian Heart Journal

Source : https://tehj.springeropen.com/articles/10.1186/s43044-023-00389-8

Background Hypercholesterolemia is a lipid disorder characterized by excessively high levels of low-density lipoproteins, which encourages fat accumulation in your arteries, hence escalating the chances of heart attack and stroke....

Conclusions: While statin treatments have been extensively researched and are strongly endorsed by randomized controlled trials and clinical guidelines, not every patient can tolerate statin therapy or attain an adequate reduction in LDL-C levels through statin treatment alone. Inclisiran provides convenience as it needs to be administered...

Profile Image
  • Saved
Impact of metformin on statin-associated myopathy risks in dyslipidemia patients - PubMed

Impact of metformin on statin-associated myopathy risks in dyslipidemia patients - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37417539/

A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and...

Conclusions/Relevance: This study found that a comedication with metformin was associated with decreased myopathy risk in statin-treated dyslipidemia patients compared to statin-only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy.

Profile Image
  • Saved
The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction

The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction

Source : https://www.dovepress.com/the-inhibition-of-evolocumab-on-non-infarct-related-artery-disease-in--peer-reviewed-fulltext-article-IJGM

Evolocumab + statin therapy could significantly improve physiological function of coronary arteries, downregulate re-hospitalization rate of STEMI pts with NIRA

Conclusion: Evolocumab combined with statin therapy can significantly improve the anatomical and physiological function of the coronary arteries and downregulate the re-hospitalization rate due to UA in STEMI patients with NIRA.

Profile Image
  • Saved

Conclusions: In contemporary practice, graft failure remains common among patients undergoing CABG and is strongly associated with adverse cardiac events.

Profile Image